HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zarnke, K. B Search for Related Content PubMed PubMed Citation Articles by Zarnke, K. B Topic Collections Relevant Article

Amlodipine plus perindopril was better than atenolol plus bendroflumethiazide for reducing complications in hypertension

Q In patients 40–79 years of age with hypertension and 3 other cardiovascular (CV) risk factors, is amlodipine plus perindopril more effective than atenolol plus bendroflumethiazide for reducing CV outcomes?

Clinical Impact Ratings GP/FP/Primary care IM/Ambulatory care Cardiology

Key Words: adrenergic ß antagonists • calcium channel blockers • cardiovascular diseases • hypertension

The first 150 words of the full text of this article appear below.

METHODS
Design randomised controlled trial (Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm [ASCOT-BPLA]).

Allocation concealed.^*

Blinding blinded (outcome assessors).^*

Follow up period median 5.5 years.

Setting 686 family practices in the Nordic countries and 32 regional centres in the UK and Ireland.

Patients 19 257 patients 40–79 years of age (mean age 63 y, 77% men) who had hypertension and 3 other CV risk factors. Exclusion criteria included previous myocardial infarction (MI), currently treated angina, and a cerebrovascular event within the previous 3 months.

Intervention amlodipine, 5–10 mg, adding perindopril, 4–8 mg as required (n = 9639), or atenolol, 50–100 mg, adding bendroflumethiazide, 1.25–2.5 mg, and potassium as required (n = 9618).

Outcomes composite end point of non-fatal MI (including silent MI) and fatal coronary heart disease. Secondary outcomes included all cause mortality, total stroke, all coronary events, total CV events and procedures, and CV mortality.

Patient follow up 100% (intention . . . [Full text of this article]

Kelly B Zarnke, MD

University of Western Ontario, London, Ontario, Canada

Relevant Article

Glossary
Evid. Based Med. 2006 11: 63a. (in Glossary) [Extract] [Full Text] [PDF]